Biomerica (BMRA) Common Equity (2011 - 2026)

Biomerica has disclosed Common Equity across 16 years of filings, most recently posting $3.3 million for Q1 2026.

• Common Equity for Q1 2026 came in at $3.3 million, down 40.06% year-over-year; the trailing twelve-month figure through Feb 2026 was $3.3 million (down 40.06% YoY), and the FY2025 annual result was $4.1 million, down 37.72% from the prior year.
• Common Equity came in at $3.3 million for Q1 2026 at Biomerica, down from $4.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $11.7 million in Q2 2023 to a low of $3.3 million in Q1 2026.
• The 5-year median for Common Equity is $6.6 million (2024), against an average of $7.0 million.
• Across the five-year window, Common Equity surged 40.83% in 2023 and plunged 50.35% in 2024, its largest moves.
• Biomerica's Common Equity stood at $7.2 million in 2022, then gained by 29.53% to $9.4 million in 2023, then plunged by 45.5% to $5.1 million in 2024, then declined by 13.28% to $4.4 million in 2025, then declined by 25.21% to $3.3 million in 2026.
• The last three Common Equity figures came in at $3.3 million (Q1 2026), $4.4 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.